髓样分化因子88在结直肠癌患者癌组织中的表达及其临床意义

doi:10.13481/j.1671-587x.20180529

吉林大学学报(医学版) ›› 2018, Vol. 44 ›› Issue (05): 1047-1051.doi: 10.13481/j.1671-587x.20180529

髓样分化因子88在结直肠癌患者癌组织中的表达及其临床意义

朱广伟, 郑炜, 黄永建, 华进, 杨树钢, 叶建新

福建医科大学附属第一医院胃肠外科二区福建医科大学消化道恶性肿瘤教育部重点实验室, 福建福州 350005

收稿日期:2017-08-20 出版日期:2018-09-28 发布日期:2018-11-20
通讯作者: 叶建新,教授,主任医师,硕士研究生导师(Tel:0591-87982082,E-mail:yjx0201@vip.sina.com) E-mail:yjx0201@vip.sina.com
作者简介:朱广伟(1983-),男,河南省郑州市人,主治医师,医学博士,主要从事消化道恶性肿瘤转移的分子机制方面的研究。
基金资助:
国家自然科学基金青年基金资助课题（81702424）；福建省科技厅自然科学基金资助课题（2017J01279）；福建省卫计委青年科研项目资助课题（2017-1-51）

Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance

ZHU Guangwei, ZHENG Wei, HUANG Yongjian, HUA Jin, YANG Shugang, YE Jianxin

Department of Gastrointestinal Surgery 2 Section, First Affiliated Hospital, Fujian Medical University;Key Laboratory of Gastrointestinal Cancer Ministry of Education, Fujian Medical University, Fuzhou 350005, China

Received:2017-08-20 Online:2018-09-28 Published:2018-11-20

摘要/Abstract

摘要： 目的：分析髓样分化因子88（MyD88）在结直肠癌患者癌组织和癌旁组织中的表达，探讨其表达与结直肠癌患者临床病理参数和预后的关系，阐明MyD88表达的临床意义。方法：收集90例结直肠癌患者的癌组织及其相对应的癌远旁组织标本并分析其临床病理资料，免疫组织化学法检测MyD88在结直肠癌及癌远旁组织中的表达，应用Image-Pro Plus 6.0软件半定量分析MyD88在不同组织中的表达水平，采用Kaplan-Meier法对90例结直肠癌患者进行生存分析。结果：MyD88在结直肠癌组织中的表达水平明显高于癌远旁组织（P<0.01）；MyD88表达水平与结直肠癌患者年龄、性别、肿瘤大小和组织学分化无明显关联（P>0.05），MyD88表达水平与结直肠癌患者临床分期、T分期、M分期和淋巴结转移状态有关联（P<0.05）；MyD88高表达组结直肠癌患者生存率明显低于MyD88低表达组（P<0.05）。结论：MyD88在结直肠癌患者癌组织中高表达，且与患者的临床分期、T分期、M分期和淋巴结转移状态有关联。

关键词: 结直肠肿瘤, 髓样分化因子88, 淋巴结转移, 预后

Abstract: Objective:To analyze the expressions of myeloid differentiation factor 88(MyD88) in cancer tissue and adjacent tissue of the patients with colorectal cancer and to explore the relationships between its expression and the clinicopathological parameters and the prognosis of the patients with colorectal cancer, and to clarify the clinical significance of MyD88 expression. Methods:A total of 90 cases of tumor tissue and adjacent tissue of the patients with colorectal cancer were collected and their clinical pathological materials were analyzed. The expressions of MyD88 in tumor tissue and adjacent tissue of the colorectal cancer patients were detected by immunohistochemistry. The expression levels of MyD88 in different tissues were analyzed by Image-Pro Plus 6.0 software. Kaplan-Meier method was used for survival analysis in the 90 patients with colorectal cancer. Results:The expression level of MyD88 in colorectal cancer tissue was significantly higher than that in adjacent colorectal cancer tissue(P<0.001). The MyD88 expression level had no correlations with the age, gender, tumor size and histologreal differentiation of the patients with colorectal cancer (P<0.05). The MyD88 expression level had correlations with the clinical stage, T stage, M stage and lymph node metastasis(P<0.05). The survival rate of the patients with colorectal cancer with higher expression of MyD88 was significantly lower than that of the patients with colorectal cancer with low expression of MyD88 (P<0.05). Conclusion:MyD88 is highly expressed in colorectal cancer tissue and it is associated with the clinical stage, T stage, M stage, and the situation of lymph node metastasis of the patients with colorectal cancer.

Key words: colorectal neoplasms, myeloid differentiation factor 88, lymph node metastasis, prognosis

中图分类号:

R735.37

朱广伟, 郑炜, 黄永建, 华进, 杨树钢, 叶建新. 髓样分化因子88在结直肠癌患者癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(05): 1047-1051.

ZHU Guangwei, ZHENG Wei, HUANG Yongjian, HUA Jin, YANG Shugang, YE Jianxin. Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance[J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1047-1051.

参考文献

[1] Wu DM, Wang YJ, Han XR, et al. Tanshinone ⅡA prevents left ventricular remodelling via the TLR4/MyD88/NF-κB signalling pathway in rats with myocardial infarction[J]. J Cell Mol Med, 2018,5(10):3058-3072.
[2] Wang YL, Wang YL. MYD88 mutations and sensitivity to ibrutinib therapy[J]. J Mol Diagn, 2018, 20(2):264-266.
[3] Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/IL-1 signaling[J]. Curr Top Microbiol Immunol, 2002, 270:155-167.
[4] 苏向前,张成海. 腹腔镜右半结肠癌CME根治术与策略[J]. 中华普外科手术学杂志:电子版,2017, 11(2):95-98.
[5] Echizen K, Oshima H, Nakayama M, et al. The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion[J]. Adv Biol Regul, 2018,68:39-45.
[6] Sikora KA, Bennett JR, Vyncke L, et al. Germline gain-of-function myeloid differentiation primary response gene-88(MYD88) mutation in a child with severe arthritis[J]. J Allergy Clin Immunol, 2018, 141(5):1943-1947.
[7] Block MS, Vierkant RA, Rambau PF, et al. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer[J]. Mayo Clin Proc,2018, 93(3):307-320.
[8] Ma L, Feng L, Ding X, et al. Effect of TLR4 on the growth of SiHa human cervical cancer cells via the MyD88-TRAF6-TAK1 and NF-kappaB-cyclin D1-STAT3 signaling pathways[J]. Oncol Lett, 2018, 15(3):3965-3970.
[9] Wang EL, Qian ZR, Nakasono M, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer[J]. Br J Cancer, 2010, 102(5):908-915.
[10] Arancibia SA, Beltrán CJ, Aguirre IM, et al. Toll-like receptors are key participants in innate immune responses[J]. Biol Res, 2007, 40(2):97-112.
[11] Sheedy FJ, O'Neill LA. The Troll in Toll:Mal and Tram as bridges for TLR2 and TLR4 signaling[J]. J Leukoc Biol, 2007, 82(2):196-203.
[12] Jin B, Sun T, Yu XH, et al. The effects of TLR activation on T-cell development and differentiation[J]. Clin Dev Immunol, 2012, 2012:836485.
[13] Kawai T, Akira S. TLR signaling[J]. Semin Immunol,2007, 19(1):24-32.
[14] An H, Qian C, Cao X. Regulation of Toll-like receptor signaling in the innate immunity[J]. Sci China Life Sci, 2010, 53(1):34-43.
[15] Zhou S, Wang G, Zhang W. Effect of TLR4/MyD88 signaling pathway on sepsis-associated acute respiratory distress syndrome in rats, via regulation of macrophage activation and inflammatory response[J]. Exp Ther Med, 2018, 15(4):3376-3384.
[16] 杜永生. MyD88在结直肠癌组织中的mRNA表达及DNA突变检测[D]. 昆明:昆明医科大学,2011.
[17] 秦艳,吴玉玉,白瑞珍, 等.结直肠腺瘤及结直肠癌中TLR7 TLR9及MyD88的表达[J]. 长治医学院学报,2013, 27(6):406-409.
[18] 于月红,钱雷,陈玮. 结直肠癌组织Toll样受体4和髓系分化蛋白88mRNA检测[J]. 海南医学,2011, 22(12):9-11.

髓样分化因子88在结直肠癌患者癌组织中的表达及其临床意义

Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	朱涛, 张国明, 严飞, 刘正, 霍强. 急性心肌梗死患者PCI术后心率变异性对主要不良心脏事件的评估价值[J]. 吉林大学学报(医学版), 2018, 44(04): 780-785.
[2]	王丹, 李怡飞, 历春, 董志恒, 董营, 盖晓东. 结直肠癌组织中B7-H1和B7-H4表达与Foxp3⁺调节性T细胞浸润的关联性[J]. 吉林大学学报(医学版), 2018, 44(03): 543-547.
[3]	高欢, 白元松, 代恩勇, 韩冷, 卢振霞, 赵亚男. 复发/难治性儿童B淋巴母细胞淋巴瘤1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 416-420.
[4]	于云鹤, 杜烨, 韩冰, 李嗣杰, 宋乐连, 范志民. 新辅助化疗对Luminal B型乳腺癌各亚组的疗效观察及预后分析[J]. 吉林大学学报(医学版), 2018, 44(02): 356-362.
[5]	范励雯, 付彤, 古林, 吴迪, 贾泓瑶, 宋东. 副乳腺癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 412-415.
[6]	何欣, 杨婷婷, 高阳阳, 宋艳秋. 乳腺癌患者心理韧性及其心理干预方式的研究进展[J]. 吉林大学学报(医学版), 2018, 44(02): 455-460.
[7]	焦洋, 杨冬野, 杨晶, 刘飞, 康喜荣, 张建生. Krüppel样转录因子12在结直肠癌患者肿瘤组织和血清中的表达及其意义[J]. 吉林大学学报(医学版), 2017, 43(06): 1204-1208.
[8]	孙慧颖, 杜波, 禹智, 刘洪泉, 于红. 突发性聋伴良性阵发性位置性眩晕病例分析并文献复习[J]. 吉林大学学报(医学版), 2017, 43(05): 1025-1029.
[9]	文思敏, 于多, 吕欣, 王铁君. 紫杉醇联合顺铂与单药顺铂2种同步放化疗方案对中晚期宫颈癌患者预后的影响及安全性评价[J]. 吉林大学学报(医学版), 2017, 43(05): 1002-1008.
[10]	苏军燕, 李迎今, 徐长妍. 急性白血病患儿白血病干细胞表面CD96和CD71的表达对其疗效和预后的影响[J]. 吉林大学学报(医学版), 2017, 43(04): 776-781.
[11]	杨冬阳, 赖晓嵘, 黎莹, 马立宇, 罗刚, 李子俊, 徐飞, 马冬. Ⅳ期结直肠癌轻微症状患者原发灶切除和KRAS基因突变对其预后的影响[J]. 吉林大学学报(医学版), 2017, 43(04): 805-811.
[12]	陈志华, 林素勇, 韩宏景, 苏小宝, 陈绍勤, 戴起宝. 慢病毒转染KISS1基因对人结直肠癌HCT116细胞增殖、侵袭和迁移能力的影响[J]. 吉林大学学报(医学版), 2017, 43(03): 577-581.
[13]	赵治艳, 盛今东, 刘宝国. 恶性甲状腺肿物和甲状腺乳头状癌Ⅵ区淋巴结转移的危险因素[J]. 吉林大学学报(医学版), 2017, 43(02): 334-338.
[14]	郝铮, 刘楠, 王路, 李东原, 赵丛海, 刘伟明, 陈卓, 张金男. 立体定向与简易定位颅内置管治疗中等量高血压脑出血患者临床效果比较[J]. 吉林大学学报(医学版), 2017, 43(01): 130-134.
[15]	程诗佳, 王旭, 崔久嵬. 肿瘤患者异常铁代谢及其在肿瘤诊断和治疗中应用的研究进展[J]. 吉林大学学报(医学版), 2017, 43(01): 200-204.